U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06933134) titled 'Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis' on March 25.
Brief Summary: Evaluation of the prediction of clinical response to rituximab at a dose of 1000 mg once using a pharmacological model including several pharmacokinetic and pharmacodynamic parameters.
Study Start Date: May, 2025
Study Type: OBSERVATIONAL
Condition:
Rheumatoid Arthritis (RA)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University Hospital, Tours
Published by HT Digital Content Services with permission from Health Daily Digest....